A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
Public ClinicalTrials.gov record NCT01270464. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to determine whether reslizumab, at a dosage of 0.3 or 3.0 mg/kg administered once every 4 weeks for a total of 4 doses, is more effective than placebo in improving lung function in patients with eosinophilic asthma as assessed by the overall change from baseline in forced expiratory volume in 1 second (FEV1).
Study identification
- NCT ID
- NCT01270464
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 315 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2011 (Type not available)
- Primary completion
- Sep 2013 (Actual)
- Completion
- Sep 2013 (Actual)
- Last update posted
- Jun 6, 2016
2011 – 2013
United States locations
- U.S. sites
- 26
- U.S. states
- 12
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 12 | Anaheim | California | — | — |
| Teva Investigational Site 11 | Fountain Valley | California | — | — |
| Teva Investigational Site 43 | Los Angeles | California | — | — |
| Teva Investigational Site 4 | Orange | California | — | — |
| Teva Investigational Site 15 | Walnut Creek | California | — | — |
| Teva Investigational Site 2 | Colorado Springs | Colorado | — | — |
| Teva Investigational Site 24 | Largo | Florida | — | — |
| Teva Investigational Site 27 | Miami | Florida | — | — |
| Teva Investigational Site 5 | Miami | Florida | — | — |
| Teva Investigational Site 19 | Tallahassee | Florida | — | — |
| Teva Investigational Site 17 | Trinity | Florida | — | — |
| Teva Investigational Site 18 | Valrico | Florida | — | — |
| Teva Investigational Site 6 | Lilburn | Georgia | — | — |
| Teva Investigational Site 3 | Savannah | Georgia | — | — |
| Teva Investigational Site 7 | Iowa City | Iowa | — | — |
| Teva Investigational Site 8 | Omaha | Nebraska | — | — |
| Teva Investigational Site 26 | Summit | New Jersey | — | — |
| Teva Investigational Site 20 | Cincinnati | Ohio | — | — |
| Teva Investigational Site 1 | Medford | Oregon | — | — |
| Teva Investigational Site 73 | Lincoln | Rhode Island | — | — |
| Teva Investigational Site 9 | Providence | Rhode Island | — | — |
| Teva Investigational Site 21 | Charleston | South Carolina | — | — |
| Teva Investigational Site 16 | Fort Worth | Texas | — | — |
| Teva Investigational Site 10 | Houston | Texas | — | — |
| Teva Investigational Site 14 | San Antonio | Texas | — | — |
| Teva Investigational Site 45 | San Antonio | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 63 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01270464, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 6, 2016 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01270464 live on ClinicalTrials.gov.